Giants of Cancer CareĀ® Program Inductees


Robert Z. Orlowski, MD, PhD

The University of Texas MD Anderson Cancer Center

  • Orlowski is chairman ad interim, director of myeloma, Florence Maude Thomas Cancer Research Professor, and professor of medicine in the departments of lymphoma/myeloma and experimental therapeutics at The University of Texas MD Anderson Cancer Center.
  • Orlowski was the first to document the clinical effectiveness of bortezomib (Velcade) in patients with multiple myeloma and mantle cell lymphoma.
  • He played a prominent role in the development of the bortezomib/doxorubicin combination and carfilzomib (Kyprolis) for patients with relapsed/refractory multiple myeloma, spearheading their development from the preclinical stage through to phase 1 and phase 3 studies.
  • His research into the ubiquitin-proteasome pathway and its link to apoptosis led to the validation of proteasome inhibitors, both alone and in combination with other agents, as rationally designed therapeutics.
  • Orlowski has developed and characterized models of drug resistance to several novel agents, including bortezomib, carfilzomib, lenalidomide (Revlimid), and pomalidomide (Pomalyst).
  • His laboratory identified the zinc finger transcription factor, ZKSCAN3, as a novel mediator of myeloma and lymphoma proliferation and the tight junction protein TJP1 as a mediator of drug resistance.
Back to 2022 Inductees